A Study Assessing Change in Sense of Smell After Rasagiline Use in Parkinson's Patients
| Status: | Completed |
|---|---|
| Conditions: | Parkinsons Disease |
| Therapuetic Areas: | Neurology |
| Healthy: | No |
| Age Range: | Any - 90 |
| Updated: | 11/30/2013 |
| Start Date: | November 2009 |
| End Date: | November 2013 |
| Contact: | Lori Sterling |
| Email: | Lsterling@thepi.org |
| Phone: | 408-542-5601 |
A Prospective Randomized Placebo-Controlled Double-Blind Study Assessing Change in Olfactory Function After Initiation of Rasagiline in Idiopathic Parkinson's Disease
A decrease or loss of the sense of smell is very common in patients with Parkinson's Disease
even in the earliest stages of the disease. There have been no treatments that have been
proven to improve sense of smell in patients with Parkinson's Disease.
Rasagiline (brand name: Azilect) was approved by the U.S. Food and Drug Administration (FDA)
on May 16th 2006 to be used by Parkinson's patients to treat the motor symptoms associated
with the disease. The purpose of this study is to see if there is change in sense of smell
after starting Rasagiline.
This study will last approximately 10 weeks.
- 2 visits to The Parkinson's Institute in Sunnyvale, California
- 1 phone call between visits
You will be asked to take either Rasagiline (Azilect) or placebo (an identical pill without
active ingredients)
- 5 in 6 chance of receiving Rasagiline (Azilect)
- 1 in 6 chance of receiving placebo
- Neither you nor the study team will know which you are assigned
- This information will be available in case of emergency
To be eligible for this study, you must:
- be 90 years old or younger
- have a decreased loss of smell or complete loss of smell
- have not taken Selegiline or Rasagiline within the past 12 months
- have not smoked within the last year
- be on a stable dose of Parkinson's medication (or not on any PD medicines)
- have no history of head trauma, nasal surgery, nasal inflammation causing congestion or
polyps, nasal/sinus infection, or prior Zicam use
- have not used decongestants, antihistamine or inhaled steroids within 2 weeks of the
study and be willing to avoid such treatments during the study
Inclusion Criteria:
- Men and women with Parkinson's Disease (PD), defined as the presence of at least two
of the cardinal signs of PD (bradykinesia, resting tremor, rigidity) without other
identifiable cause of parkinsonism or signs of atypical parkinsonism
- Functional hyposmia or anosmia, as defined by UPSIT scores less than the 25th
percentile for age- and gender-matched norms
- Have been on stable dose of PD medications for at least 30 days
- Age < or = 90 years
- Willing and able to give informed consent
- Women of child-bearing potential may participate provided they are willing to use
adequate contraceptive methods during the duration of the study. Women of
childbearing potential must have a negative pregnancy test at the screening visit and
be non-lactating.
Exclusion Criteria:
- Prior use of an MAO inhibitor, including selegiline or rasagiline within the last 12
months
- Presence of other conditions that in the investigator's opinion may significantly
cause olfactory impairment, including prior head trauma, nasal surgery, nasal
inflammation causing concurrent congestion or polyps, nasal or sinus infection, prior
intranasal zinc salt (Zicam) use, history of smoking within the past year
- Presence of dementia or significant cognitive impairment with Mini-Mental State
Examination (MMSE) < 24
- Present of a medical or surgical condition which in the opinion of the investigator
would preclude participation in and completion of study procedures
- Use of any experimental medication within 60 days of baseline
- Use of decongestants, antihistamines, inhaled steroids within 2 weeks of baseline
- Use of any medication contraindicated with use of rasagiline (Investigator will take
into consideration concomitant antidepressant use as per prescribing information
guidelines for rasagiline)
We found this trial at
1
site
Click here to add this to my saved trials
